Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) (NCT06691984)

🧪 Interventions in This Study

• Xaluritamig (DRUG)
• Abiraterone (DRUG)
• Enzalutamide (DRUG)
• Cabazitaxel (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (164 Sites)

Showing the first 25 of 164 sites.

• University of Alabama at Birmingham — Birmingham, Alabama
• City of Hope National Medical Center — Duarte, California
• Providence Saint Jude Medical Center — Fullerton, California
• Cedars Sinai Medical Center — Los Angeles, California
• University of California Irvine — Orange, California
• University of California San Francisco — San Francisco, California
• University of Florida, College of Medicine — Gainesville, Florida
• Sylvester Comprehensive Cancer Center-Fox Building — Miami, Florida
• AdventHealth Orlando — Orlando, Florida
• University of Chicago — Chicago, Illinois
• Indiana University — Indianapolis, Indiana
• University of Louisville Health - James Graham Brown Cancer Center — Louisville, Kentucky
• Norton Cancer Institute — Louisville, Kentucky
• Massachusetts General Hospital — Boston, Massachusetts
• Beth Israel Deaconess Medical Center — Boston, Massachusetts
• Dana-Farber Cancer Institute — Boston, Massachusetts
• Henry Ford Hospital, Henry Ford Health Systems — Detroit, Michigan
• University of Minnesota — Minneapolis, Minnesota
• Washington University — St Louis, Missouri
• Yale New Haven Hospital — New York, New York
• Memorial Sloan Kettering Cancer Center — New York, New York
• Montefiore Medical Center — The Bronx, New York
• Levine Cancer Institute — Charlotte, North Carolina
• Duke University Medical Center Duke Cancer Center — Durham, North Carolina
• Sanford Roger Maris Cancer Center — Fargo, North Dakota

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Castration-resistant Prostate Cancer

• A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer — San Francisco, California
• Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment — Tucson, Arizona
• ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC — Sacramento, California
• FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Duarte, California
• A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer — Duarte, California
• FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer — San Francisco, California

Explore by condition: All Metastatic Castration-resistant Prostate Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.